CLOV
Clover Health Investments, Corp.
NASDAQ NMS - GLOBAL MARKET· Health Care· US· IPO 2020-06-12
$4.29
-0.02 (-0.46%)
last quote
Want the full multi-source brief on CLOV?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$4.29
High
$4.37
Low
$4.19
Previous close
$4.31
Fundamentals
Market cap
$2.28B
P/E (TTM)
—
P/S (TTM)
0.92x
P/B
4.63x
Gross margin
—
Operating margin
-0.74%
Net margin
-0.74%
Rev growth (YoY)
54.03%
EPS growth (YoY)
—
ROE
-5.38%
52W high
$5.59
52W low
$1.58
Beta
2.63x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-04todayafter market
Q3 2026EPS est $0.00Rev est $753.0M
Recent SEC filings
CIK 1801170filing-language history →
Recent news
2026-10-28 → 2026-11-04
Benzinga · 5d
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Analysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).
Benzinga · 5d
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.
Yahoo · 6d
3 Big reasons to love Clover Health (CLOV)
What a time it’s been for Clover Health. In the past six months alone, the company’s stock price has increased by a massive 74.4%, reaching $4.61 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Yahoo · 6d
Clover Health climbs after Needham initiates coverage with Buy, $6 target
Investing.com -- Clover Health Investments Corp (NASDAQ:CLOV) shares advanced 4% in Wednesday trading after Needham initiated coverage on the healthcare technology company with a Buy rating and a $6.00 price target. The brokerage highlighted Clover’s proprietary technology platform and improving cohort economics as primary drivers that could underpin long-term earnings expansion.
Benzinga · 7d
This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Hold ALHC; Overweight/$6 SPRO; Buy/$3 LABT; Buy/$6 CLOV.
Benzinga · 7d
Needham Initiates Coverage On Clover Health Investments with Buy Rating, Announces Price Target of $6
Needham analyst Matthew Shea initiates coverage on Clover Health Investments (NASDAQ:CLOV) with a Buy rating and announces Price Target of $6.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial